Foghorn Therapeutics (FHTX) Projected to Post Quarterly Earnings on Monday

Foghorn Therapeutics (NASDAQ:FHTX) is expected to issue its Q1 2025 quarterly earnings data before the market opens on Monday, May 5th. Analysts expect the company to announce earnings of ($0.30) per share and revenue of $4.96 million for the quarter.

Foghorn Therapeutics (NASDAQ:FHTX) last issued its quarterly earnings results on Thursday, March 6th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.13. The firm had revenue of $2.86 million for the quarter, compared to the consensus estimate of $8.56 million. On average, analysts expect Foghorn Therapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Foghorn Therapeutics Trading Down 2.5 %

Shares of NASDAQ:FHTX opened at $4.36 on Monday. The company has a market capitalization of $242.47 million, a price-to-earnings ratio of -2.27 and a beta of 3.16. Foghorn Therapeutics has a 12 month low of $2.94 and a 12 month high of $10.25. The firm’s 50-day moving average is $4.16 and its 200 day moving average is $5.51.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on FHTX shares. HC Wainwright reiterated a “buy” rating and set a $13.00 price target on shares of Foghorn Therapeutics in a report on Friday, March 7th. Citizens Jmp started coverage on shares of Foghorn Therapeutics in a research note on Wednesday, April 23rd. They set a “mkt outperform” rating and a $9.00 price target for the company. Citigroup initiated coverage on Foghorn Therapeutics in a research note on Wednesday. They issued an “outperform” rating on the stock. B. Riley initiated coverage on Foghorn Therapeutics in a research report on Thursday, January 30th. They set a “buy” rating and a $10.00 target price for the company. Finally, JMP Securities initiated coverage on Foghorn Therapeutics in a research report on Wednesday, April 23rd. They set a “market outperform” rating and a $9.00 target price for the company. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Foghorn Therapeutics presently has a consensus rating of “Buy” and an average target price of $12.13.

About Foghorn Therapeutics

Foghorn Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.